My Healthcare News & Research — March 25, 2026

Platinum-resistant ovarian cancer is one of the hardest situations in all of oncology. When the disease stops responding to platinum chemotherapy, the drugs that remain tend to buy only a few months, and for decades almost nothing new moved that number. In early 2026 something finally did. The U.S. Food and Drug Administration approved a first-of-its-kind drug that works by an entirely new mechanism — blocking the stress hormone cortisol inside tumor cells — and a large, well-run trial showed it helped women live meaningfully longer. Here is what was approved, what the evidence actually says, and the honest limits of what it can do.

Table of Contents

  1. 1. A First-in-Class Drug Wins FDA Approval
  2. 2. What the ROSELLA Trial Actually Showed
  3. 3. How It Works: Blocking Cortisol's Escape Hatch
  4. 4. What It Means for Patients
  5. 5. Honest Caveats
  6. 6. The Practical Takeaway
  7. Sources
  8. Featured Videos

1. A First-in-Class Drug Wins FDA Approval

On March 25, 2026, the FDA approved relacorilant — brand name Lifyorli, made by Corcept Therapeutics — in combination with the chemotherapy drug nab-paclitaxel (Abraxane). The approval covers adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have already received one to three prior systemic treatment regimens, at least one of which included the anti-angiogenic drug bevacizumab (Avastin).

What makes this notable is not just another line of therapy for a crowded field — it is that the field was nearly empty. Relacorilant is the first FDA-approved selective glucocorticoid receptor antagonist (SGRA), a genuinely new class of cancer medicine. It does not attack the tumor directly. Instead it removes a defense the tumor uses to survive chemotherapy. That is a different idea from almost everything else on the ovarian-cancer shelf, and it is why oncologists have paid close attention.

2. What the ROSELLA Trial Actually Showed

The approval rests on a single, well-designed phase 3 study called ROSELLA (also known as GOG-3073 and ENGOT-ov72). It enrolled 381 women with platinum-resistant ovarian cancer and randomly assigned them, in a coin-flip 1:1 split, to receive either relacorilant plus nab-paclitaxel or nab-paclitaxel alone. Because it is a randomized comparison against the real standard-of-care chemotherapy, the results carry weight that a single-arm study never could.

Two numbers matter most:

The overall-survival results were presented on April 10, 2026 at the Society of Gynecologic Oncology annual meeting and published the same day in The Lancet. The earlier progression-free-survival results had been reported at the 2025 ASCO meeting.

3. How It Works: Blocking Cortisol's Escape Hatch

Chemotherapy kills cancer cells by pushing them into a self-destruct program called apoptosis. It turns out that cortisol — the body's main stress hormone — can quietly switch that program off. When cortisol binds to the glucocorticoid receptor inside a tumor cell, it can activate survival signals that blunt the effect of chemotherapy. Ovarian tumors express this receptor, and higher activity has been linked to worse outcomes and chemotherapy resistance.

Relacorilant blocks that receptor. By keeping cortisol from flipping the survival switch, it is designed to make the accompanying chemotherapy work the way it is supposed to. An older, non-selective version of this idea (the drug mifepristone) also blocks the progesterone receptor and carries hormonal side effects; relacorilant was engineered to be selective for the glucocorticoid receptor, which is what allowed it to be combined with chemotherapy at meaningful doses.

4. What It Means for Patients

For a woman whose ovarian cancer has become platinum-resistant and who has already been through bevacizumab, the options have long been limited and the conversations difficult. This approval adds a real, evidence-backed choice that — on average — extended life by several months and did so through a mechanism that does not overlap with the drugs she has already tried. In a setting where progress has been measured in weeks, months of additional survival is not a small thing.

It is also a proof of concept with a longer reach. If blocking cortisol signaling can restore chemotherapy's punch in ovarian cancer, the same strategy is now being explored in other cortisol-sensitive tumors. This first approval is the beginning of a story, not the end of one.

5. Honest Caveats

Several things are worth holding onto so the headline does not outrun the reality.

This is a treatment, not a cure. The median survival went from about 12 to 16 months. That is a genuine and welcome gain, but the disease in this setting remains very serious, and the benefit is measured in months, not years.

Relative versus absolute benefit. A “35% reduction in the risk of death” sounds larger than “4 more months of median survival,” yet both describe the same result. The relative figure is the honest statistic; the absolute figure is what it feels like in a life. Individual results vary widely around a median — some women benefit far more, some not at all.

It applies to a specific group. The approval is for platinum-resistant disease after one to three prior regimens including bevacizumab. It is not a first-line therapy, it was not tested in platinum-sensitive disease, and it is given with chemotherapy, not instead of it — so the side effects of nab-paclitaxel still apply, plus whatever the combination adds. Any decision belongs in a detailed conversation with a gynecologic oncologist.

6. The Practical Takeaway

If you or someone you love is living with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer and has previously received bevacizumab, it is worth asking the oncology team directly whether relacorilant (Lifyorli) plus nab-paclitaxel is an appropriate option. It is now FDA-approved, backed by a randomized phase 3 trial, and works by a mechanism unlike the therapies that came before it. For everyone else, it is a reminder that even in the most stubborn cancers, a genuinely new idea can still move the needle.

Sources

Back to Table of Contents